Drug Profile


Alternative Names: huMAb IL-17; RG 4934; RO 5310074

Latest Information Update: 31 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psoriatic arthritis

Most Recent Events

  • 26 Jul 2012 Discontinued - Phase-I for Psoriatic arthritis in Australia (IV)
  • 26 Jul 2012 Discontinued - Phase-I for Psoriatic arthritis in USA (IV)
  • 28 Feb 2011 Phase-I clinical trials in Psoriatic arthritis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top